The stage of a tumor refers to the extent to which lung cancer has spread in the body. Staging involves both evaluation of a tumor's size as well as the presence or absence of metastases in the lymph nodes or in other organs. Staging is important for determining how a particular tumor should be treated. Staging of a tumor is also critical in estimating the prognosis of a given patient, with higher-stage tumors having a worse prognosis than lower-stage tumors.
Doctors use several tests to accurately stage lung cancer, including blood tests, X-rays, CT scans, bone scans, and PET scans. An abnormal blood chemistry test may signal the presence of metastases in the bone or liver. Radiological procedures document the size of a tumor, as well as its spread to other organs.
Based on the Surveillance, Epidemiology, and End Registry, the estimated incidence of stage IIIB NSCLC is 17.6%. The anticipated 5-year survival for the vast majority of patients who present with clinical stage IIIB NSCLC is 3% to 7%. In small case series, selected patients with T4, N0-1 disease, solely as the result of satellite tumor nodule(s) within the primary lobe, have been reported to have 5-year survival rates of 20%.[3,4][Level of evidence: 3iiiA]
Standard Treatment Options...